New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diphenhydramine hydrochloride 25mg; methaqualone 250mg - capsule - 250mg/25mg - active: diphenhydramine hydrochloride 25mg methaqualone 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

roussel laboratories limited - methaqualone diphenhydramine hydrochloride - capsule

Ireland - English - HPRA (Health Products Regulatory Authority)

roussel laboratories limited - methaqualone diphenhydramine hydrochloride - tablets

Singapore - English - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - methaqualone (mtql) is an in vitro diagnostic test for the qualitative and semiquantitative detection of methaqualone and its metabolites in human urine on cobas c systems at a cutoff concentration of 300 ng/ml.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - methaqualone 150mg - tablet - 150 mg - active: methaqualone 150mg

Singapore - English - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - clinical toxicology - the emit® ii plus methaqualone assay is a homogeneous enzyme immunoassay with a 300 ng/ml cutoff. the assay is intended for use in the qualitative and semiquantitative analyses of methaqualone in human urine. emit® ii plus assays are designed for use with a number of chemistry analyzers.

Singapore - English - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical toxicology - roche diagnostics cobas integra methaqualone (mtql) is an in vitro diagnostic test for the semiquantitative and qualitative detection of methaqualone and its metabolites in human urine at a cutoff concentration of 300 ng/ml on cobas integra systems

Ireland - English - HPRA (Health Products Regulatory Authority)

e. merck ltd - methaqualone - tablets

Singapore - English - HSA (Health Sciences Authority)

fisher scientific pte ltd - clinical chemistry - the dri® methaqualone assay is intended for the qualitative and semiquantitative determination of methaqualone in human urine. hs code 30029000

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: - motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. - autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. - apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. - vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. the above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. however, mild depressive symptoms are common in gad. the effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad. however, in a study of long-term use, 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect. therefore, the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient. buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. the use of monoamine oxidase inhibitors (maois) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. the use of buspirone within 14 days of stopping an maoi intended to treat depression is also contraindicated. starting buspirone in a patient who is being treated with reversible maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings , dosage and administration and drug interactions ). buspirone hydrochloride is not a controlled substance. in human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence. human volunteers with a history of recreational drug or alcohol usage were studied in two double-blind clinical investigations. none of the subjects were able to distinguish between buspirone hydrochloride tablets and placebo. by contrast, subjects showed a statistically significant preference for methaqualone and diazepam. studies in monkeys, mice, and rats have indicated that buspirone lacks potential for abuse. following chronic administration in the rat, abrupt withdrawal of buspirone did not result in the loss of body weight commonly observed with substances that cause physical dependency. although there is no direct evidence that buspirone hydrochloride tablets cause physical dependence or drug-seeking behavior, it is difficult to predict from experiments the extent to which a cns-active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone hydrochloride tablets misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).